Enrollment completed in Ph 2/3 COMPANION-002 trial of CTX-009 + paclitaxel in patients with 2L advanced Metastatic or Recurrent Biliary Tract Cancers (BTC) August 13, 2024
FDA Clears IND Application for Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST) August 13, 2024
Supplemental NDA of Opdivo – Yervoy Combo submitted in Japan to Expand the Use for Unresectable HCC August 13, 2024
Topline Data From ASPEN-06 Ph 2 Trial shows Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer August 7, 2024
FAILED TRIAL: Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies show primary endpoint of OS improvement not achieved August 6, 2024
FDA grants Orphan Drug Designation for Avutometinib and Defactinib for the Treatment of Pancreatic Cancer August 6, 2024
EMA validated Type II Application for Opdivo plus Yervoy for 1L Treatment of Unresectable or Advanced HCC July 23, 2024
RMC-6236 to advance to Ph 3 testing in pancreatic cancer following encouraging results from a Ph 1 study July 23, 2024
End-of-Phase-2 Meeting Outcomes and Topline Interim Ph 2 Data for BOT/BAL in MSS Colorectal Cancer announced July 23, 2024
Plans for Near-Term Resubmission of NDA for 1L Treatment Option for Unresectable HCC Following Type A FDA Meeting Reported July 17, 2024
Application filed for for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer July 17, 2024
Third Independent Safety Review of Ph 3 ASPIRE Clinical Trial Announced; DSMB Recommended Continuation with No Trial Modification July 1, 2024
Planned Combination Strategy for EO-3021 in Patients with Gastric or GEJ Cancer Announced July 1, 2024
Substantial OS Benefit and Unprecedented DoR in the 18-Month Analysis from Mitazalimab OPTIMIZE-1 Ph 2 Study in 1L Pancreatic Cancer Announced July 1, 2024
Positive Initial Data Announced from Ph 1 MINOTAUR Trial of Lunresertib in Combination with FOLFIRI July 1, 2024
